A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301)

被引：0

作者：

Zhang, A. ^{[1
]}

Boni, V. ^{[2
]}

Hanson, A. ^{[3
]}

Mantia, C. ^{[4
]}

Weickhardt, A. ^{[5
]}

Yu, E. ^{[6
]}

Gupta, S. ^{[7
]}

Robert, M. ^{[8
]}

Iyer, G. ^{[9
]}

Millward, M. ^{[10
]}

Morales-Barrera, R. ^{[11
]}

Hoimes, C. ^{[12
]}

Berlin, J. ^{[13
]}

Mittal, K. ^{[14
]}

Hill, A. ^{[15
]}

Racca, F. ^{[16
]}

Pouessel, D. ^{[17
]}

Lihou, C. ^{[18
]}

Tran, B. ^{[19
]}

Loriot, Y. ^{[20
]}

机构：

[1] Macquarie Univ Hosp, Med Oncol, Sydney, NSW, Australia

[2] Next Oncol Madrid, Med Oncol, Madrid, Spain

[3] Princess Alexandria Hosp, Med Oncol, Woolloongabba, Qld, Australia

[4] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[5] Austin Hlth, Med Oncol, ONJ Canc Res Inst, Victoria, Australia

[6] Fred Hutchinson Canc Ctr, Med Oncol, Seattle, WA USA

[7] Cleveland Clin, Med Oncol, Cleveland, OH 44106 USA

[8] Inst Cancerol Ouest, Med Oncol, St Herblain, France

[9] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[10] Linear Clin Res Ctr, Med Oncol, Perth, WA, Australia

[11] Vall Hebron Inst Oncol, Med Oncol, Barcelona, Spain

[12] Duke Canc Ctr, Med Oncol, Durham, NC USA

[13] Vanderbilt Ingram Canc Ctr, Med Oncol, Nashville, TN USA

[14] UMass Mem Med Ctr, Med Oncol, Worcester, MA USA

[15] Tasman Hlth, Med Oncol, Southport, Qld, Australia

[16] Next Oncol Barcelona, Med Oncol, Barcelona, Spain

[17] IUCT Oncopole, Med Oncol, Toulouse, France

[18] Tyra Biosci, Clin Dev, Carlsbad, CA USA

[19] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Australia

[20] Inst Gustave Roussy, Med Oncol, Paris, France

来源：

EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷

关键词：

D O I：

10.1016/j.ejca.2024.114563

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S15 / S16

页数：2